Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

被引：0
|
作者：
Aziz Zaanan
Juliette Palle
Emilie Soularue
Florence Leroy
Samy Louafi
David Tougeron
Sylvain Manfredi
Pascal Artru
Astrid Pozet
Julien Taieb
机构：
[1] European Georges Pompidou Hospital,Department of Gastroenterology and Digestive Oncology
[2] Assistance Publique-Hôpitaux de Paris,Department of Medical Oncology
[3] Paris Descartes University,Department of Gastroenterology and Digestive Oncology
[4] Sorbonne Paris Cité,Department of Cancer Medicine
[5] Saint Antoine Hospital,Department of Oncology
[6] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology
[7] Saint-Louis Hospital,Department of Gastroenterology and Digestive Oncology
[8] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology and Digestive Oncology
[9] Gustave Roussy Institute,Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098
[10] Oncology Federation of Essonne,undefined
[11] Poitiers University Hospital,undefined
[12] Rennes University Hospital,undefined
[13] Jean Mermoz Hospital,undefined
[14] Besançon University Hospital,undefined
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 112
页数：5
相关论文
共 50 条
  • [1] Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
    Zaanan, Aziz
    Palle, Juliette
    Soularue, Emilie
    Leroy, Florence
    Louafi, Samy
    Tougeron, David
    Manfredi, Sylvain
    Artru, Pascal
    Pozet, Astrid
    Taieb, Julien
    TARGETED ONCOLOGY, 2018, 13 (01) : 107 - 112
  • [2] Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
    Palle, Juliette
    Tougeron, David
    Pozet, Astrid
    Soularue, Emilie
    Artru, Pascal
    Leroy, Florence
    Dubreuil, Olivier
    Sarabi, Matthieu
    Williet, Nicolas
    Manfredi, Sylvain
    Martin-Babau, Jerome
    Rebischung, Christine
    Ben Abdelghani, Meher
    Evesque, Ludovic
    Dreanic, Johann
    Hautefeuille, Vincent
    Louafi, Samy
    Sefrioui, David
    Savinelli, Francesco
    Mabro, May
    Rousseau, Benoit
    Lecaille, Cedric
    Bouche, Olivier
    Louvet, Christophe
    Lecomte, Thierry
    Bonnetain, Franck
    Taieb, Julien
    Zaanan, Aziz
    ONCOTARGET, 2017, 8 (60) : 101383 - 101393
  • [3] Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A multicenter AGEO study.
    Palle, Juliette
    Tougeron, David
    Pozet, Astrid
    Soularue, Emilie
    Artru, Pascal
    Le Roy, Florence
    Dubreuil, Olivier
    Sarabi, Matthieu
    Williet, Nicolas
    Manfredi, Sylvain
    Martin-Babau, Jerome
    Rebischung, Christine
    Ben Abdelghani, Meher
    Evesque, Ludovic
    Dreanic, Johann
    Hautefeuille, Vincent
    Louvet, Christophe
    Lecomte, Thierry
    Taïeb, Julien
    Zaanan, Aziz
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4647 - 4656
  • [5] Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study *
    Frydman, Anne-Esther
    Drouillard, Antoine
    Soularue, Emilie
    Dubreuil, Olivier
    Zaanan, Aziz
    Turpin, Anthony
    Tougeron, David
    Doat, Solene
    Bachet, Jean -Baptiste
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 198 - 205
  • [6] Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A retrospective real world study.
    Chen, Yang
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study
    Soularue, Emilie
    Cohen, Romain
    Tournigand, Christophe
    Zaanan, Aziz
    Louvet, Christophe
    Bachet, Jean-Baptiste
    Hentic, Olivia
    Samalin, Emmanuelle
    Chibaudel, Benoist
    de Gramont, Aimery
    Andre, Thierry
    BULLETIN DU CANCER, 2015, 102 (04) : 324 - 331
  • [8] Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
    Verhoeven, R. H. A.
    Kuijper, S.
    Lordick, F.
    Slingerland, M.
    Qin, A.
    van Laarhoven, H. W. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S878 - S878
  • [9] QUALITY OF LIFE RESULTS FROM A PHASE III STUDY OF TRASTUZUMAB PLUS CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION CANCER
    Ohtsu, A.
    Wang, L.
    Lim, H.
    Gourbounova, V
    Bang, Y.
    Van Cutsem, E.
    Al-Sakaff, N.
    Lehle, M.
    Hill, J.
    de Mendoza, Hurtado F.
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 14
  • [10] Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study.
    Makiyama, Akitaka
    Shimokawa, Mototsugu
    Kashiwada, Tomomi
    Takahashi, Ikuo
    Emi, Yasunori
    Kusumoto, Tetsuya
    Yamamoto, Kazuharu
    Ishikawa, Hiroshi
    Negoro, Yuji
    Oki, Eiji
    Saeki, Hiroshi
    Kakeji, Yoshihiro
    Baba, Hideo
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345